THERAPY OF HYPERACTIVE URINARY BLADDER: EXPANSION OF HORIZONS
https://doi.org/10.21518/2079-701X-2016-10-140-142
Abstract
Hyperactive urinary bladder (HUB) is one of the most frequent disturbances of the urination. Hyperactive urinary bladder (HUB) is a syndrome characterized by presence of imperative uriesthesia accompanied and not accompanied by urgent urinary incontinence usually in combination with frequent urination and nocturia with proved lack of infection and other evident pathologic changes. Pharmacotherapy is a priority method of HUB therapy. The major group of drugs is m-cholinblockers (tolterodine, oxybutinine, trospium chloride, solifenacin). Solifenacin is a modern and effective drug for therapy of HUB that has limitations on indications such as closed- ngle glaucoma, retention of urine, grave gastrointestinal diseases, myasthenia gravis. Mirabegron is the first β3-adrenoreceptor antagonist for therapy of HUB that proved its effectiveness in patients ho previously received therapy by m-cholinolytics. Mirabegron can be used at glaucoma and myasthenia, it doesn’t cause acute urine retention.
About the Author
E. I. KARPOV
Municipal Hospital No.6, Medical Center Garmonia
Russian Federation
Russian Federation
PhD in medicine
Ryazan
References
1. Milsom I, Abrams P, Cardoso L, et. al. How widespread are the symptoms of an overactive bladder and how are they managed? A population- based prevalence study. BJU Int, 2001, 87(9): 760-6.
2. Гориловский М.Л., Лахно Д.А. Гиперактивность мочевого пузыря. РМЖ, 2005, 13(25): 1691-1694./Gorilovskiy M.L., Lakhno D.A. Hyperactivity of urinary bladder. RMZ, 2005, 13 (25): 1691-1694.
3. Verner P. Tolterodin – profile leciv. Farmakologie, 2005, 5: 464-469.
4. Irwin D.E.. Milsom I, Huskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol, 2006, 50(6): 0306-14.
5. Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology, 2003, 62 (5 Suppl 2): 28-37, discussion 40-2.
6. Abrams P, Artibani W, Cardoso L et. al. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn, 2009, 28(4): 287.
7. Клинические рекомендации Европейской ассоциации урологов, 2014. М., 2014. 968 с. / Clinical Recommendations of European Urologist Association, 2014. M., 2014, 968 p.
8. Гаджиева З.К. Нарушения мочеиспускания: руководство. Под ред. Ю.Г. Аляева. М.: ГЭОТАР-Медиа, 2010. 176 с. / Gadjieva Z.K. Disturbances of urination: Guidance. Ed. by Y.G. Alyaev. M.: GEOTARMedia, 2010,176 p.
9. Benner JS, Nichol MB, Rovner ES et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int, 2010, 105(9): 1276-82.
10. Compion G, Jackson J, Jenes J. Reasons for switching antimuscarinic therapy: Results from a European cross-sectional survey of physicians, and patients with OAB. Poster presented at the European Association of Urology Annual Meeting 2012. Poster 691.
11. Khullar V, Amarenco G, Angulo J.C., et al. Efficacy and tolerability of mirabegron, a 3-adrenoreceptor agonist, in patients with overactive bladder: results from a randomized European-Australian Phase 3 Trial. Eur Urol, 2013, 63(2): 283-95.
12. Novack GD, Lewis RA, Vogel R et al. Randomized, double-masked, placebo- controlled study to assess the ocular safety of mirabegron in healthy volunteers. J Ocul Pharmacol Ther, 2013 Apr 15, Epub ahead of print.
13. Astellas Pharma Europe Ltd. BetmigaTM Summary of Product Characteristics. January 2013.
Review
For citations:
KARPOV EI. THERAPY OF HYPERACTIVE URINARY BLADDER: EXPANSION OF HORIZONS. Meditsinskiy sovet = Medical Council. 2016;(10):140-142. (In Russ.) https://doi.org/10.21518/2079-701X-2016-10-140-142
Views:
1315
Email this article 